2013 EACPT Geneva Congress Symposia: How to become a self-empowered patient?

-->

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on how to become a self-empowered patient

An empowered patient is defined as an individual being an active member of his/her disease management team and being able to make decisions consistent with his/her values. Thus conceived, the concept of empowerment is a real paradigm shift for patients and for health professionals. The relation between the physician and the patient is moving from a “the powered physician to the self-powered patient” and the fast growing access to Internet is accelerating the shift. This session will discuss how this new form of “Doctor-patient relationship” may impact on drug therapy and compliance as well as on clinical research.

2013 EACPT Congress

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congress Symposia: New targets for pain treatment

-->

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on new targets for pain treatment

Chronic pain and neuropathic pain in particular are a medical challenge as they are poorly responsive to classical peripheral anti-inflammatory or powerful, centrally-acting analgesics.

Since our understanding of the mechanisms generating pain has noticeably increased, the idea of targeting key molecules has emerged and a mechanism-based approach to treatment has been advocated. This concept will be discussed in this session, from a basic science point of view as well as with the clinical example of HIV neuropathy.

Oral short communications will be selected abstracts are most welcome!

2013 EACPT Congress

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congress Symposia: New developments in TDM

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on New developments in TDM

The development and implementation of rational, evidence-based approaches for the monitoring of medicinal therapies belong to the agenda of Clinical Pharmacology. The principles and challenges of therapeutic monitoring in the broad sense will be reviewed during this session. Further emphasis will be put on the monitoring of circulating drug concentrations, illustrated with the particular case of novel anticancer agents among other candidates to target drug concentration-triggered interventions. Recent developments will be presented and discussed in view of current needs for patients to benefit from the best possible dosage adjustment for drug treatments.

2013 EACPT Congress

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congess Symposia: PK/PD modeling

-->

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on PK/PD modeling

Population pharmacokinetic and pharmacodynamic modeling is used for exploratory analyses in the clinical development of new drugs or during post-marketing studies.  The advantages of such an approach are the collection of data in the target population, the assessment of the variability within this population and, hopefully, the discovery of factors that control this variability. The present and future developments of this discipline will be outlined with regard to regulatory acceptance, extension to mechanistic-based and disease progression modeling, and application to treatment optimization, exemplified by a panel of illustrative studies.

2013 EACPT Congress

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congress Symposia: Clinical trial regulation, control and benefits

-->

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on clinical trial regulation, control and benefits

In July 2012, the European Commission adopted a proposal for a Regulation on Clinical Trials. This is now under discussion by the European Parliament and the Council. Input from affected stakeholders is deemed also critical to end up in an optimised legislative framework for clinical trials in Europe. During next year the discussion process should be reaching its end. This session will be a unique opportunity to share and discuss first hand opinions from two key stakeholders intervening in clinical trials, regulatory bodies and academia, and discuss together benefits and risks associated to the legislative proposal.

2013 EACPT Congress

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congress Symposia: Inflammatory disease and biotherapeutics

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on Inflammatory disease and biotherapeutics

The development of biotherapeutics has considerably expanded during the last decade with the formidable improvement of biotechnological tools and better validation of targets. Inflammatory disorders represent indications of choice for the development of biotherapeutics. An intense competition is taking place currently to find new treatments for disorders against which the therapeutic armamentarium has remained limited for a long time. This session will focus on the latest therapeutic developments in the field of neurological and rheumatologic inflammatory disorders and discuss the promise but also the limitations of these new approaches.

2013 EACPT Congress

Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org 

2013 EACPT Geneva Congress Symposia: Drug-Drug Interactions

Abstract submission is now open for the next EACPT Congress, to be held in Geneva 28-31 August 2013. The congress includes symposia, keynote lectures and peer-reviewed oral and poster communications

Symposium on Drug-Drug Interactions

Drug-drug interaction is one of the major problems in therapeutics associated with the use of drugs. Given the aging of the population, polymedication and the continuous development of new drugs, the occurrence of clinically significant drug-drug interactions will dramatically increase. Metabolic enzymes as well as drug transporters are frequently involved in DDI. In vitro-in vivo extrapolation (IVIVE) methodology is widely used in drug discovery and huge effort in both academia and industry has focused on developing reliable methods to predict DDI. During this session, you will have the opportunity to discuss with international experts in the field the state of the art in predicting the magnitude of DDI at the individual level, the clinical pertinence and the role of transporters in drug interactions.

EACPT Congress 2103
Over 900 participants are expected to attend including health professionals, scientists, policy makers, biotechnology and pharmaceutical professionals, and others with an interest in basic and clinical pharmacology, pharmacotherapy, drug discovery and development, regulatory affairs and related areas.

See here for more on key themes of the Congress.

EACPT Geneva 2013 Congress website  www.eacpt2013.org